Home rehabilitation program for patients with muscular dystrophies
Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project
This study tests a home rehabilitation program for people with muscular dystrophies to see if personalized exercise plans and remote support from physiotherapists can help improve their strength and well-being.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Eugenio Medea Academic / other |
| Locations | 1 site (Bosisio Parini, Lecco) |
| Trial ID | NCT06378203 on ClinicalTrials.gov |
What this trial studies
This project aims to provide a tele-rehabilitation program for patients with muscular dystrophies, focusing on continuity of care from hospital to home. It involves creating personalized therapeutic plans that patients can follow independently at home, supported by remote monitoring from physiotherapists. The program includes 15 training sessions to enhance muscle strength and endurance, while also addressing psychological well-being. The effectiveness of this approach will be evaluated over a 6-month period.
Who should consider this trial
Good fit: Ideal candidates are individuals with a confirmed genetic diagnosis of specific types of muscular dystrophies who can walk independently in a protected environment.
Not a fit: Patients with severe cardiac or respiratory conditions may not benefit from this rehabilitation program.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and physical capabilities of patients with muscular dystrophies.
How similar studies have performed: Previous studies have shown positive outcomes with tele-rehabilitation approaches for similar conditions, indicating potential for success in this pilot project.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:- definite genetic diagnosis of Limb Girdle Muscular Dystrophy: LGMD2A/R1(calpain 3 deficiency), LGMD2B/R2(dysferlin deficiency), LGMD2I/R9 (FKRP), LGMD2L /R11(ANOCTAMIN 5) or Facio Scapulo Humeral Dystrophy (FSHD) or Becker muscular dystrophy (BMD); * strength values at the level of the main antigravity muscles \> or equal to 3, according to the Medical Research Council (MRC) scale; * independent walking in a protected (internal) environment, even with assistance; * patients must have performed at least 1 clinical-functional evaluation at our facility in the year preceding the start of the trial. * They must express compliance with joining the project and must not be followed from a physiotherapeutic point of view elsewhere during the 6 months of participation in the project. Exclusion Criteria: * dilated or ischemic heart disease with Left Ventricle Ejection Fraction \<50%; * chronic respiratory failure with Forced Vital Capacity \< 40% predicted, nocturnal oxygen desaturation - \> 5% of nocturnal time spent with peripheral oxygen saturation levels \< 90).
Where this trial is running
Bosisio Parini, Lecco
- Scientific Institute IRCCS Eugenio Medea — Bosisio Parini, Lecco, Italy (Recruiting)
Study contacts
- Study coordinator: Maria G D'Angelo
- Email: grazia.dangelo@lanostrafamiglia.it
- Phone: 031877111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.